About 44 million XRP worth $51 million, stolen from Binance, were moved overnight and mostly converted to Bitcoin through THORChain. As of Nov. 7, 148 million XRP valued at $173 million still remain in theft-linked addresses. Additionally, around 2,300 BTC worth $175 million were transferred to new Bitcoin addresses after conversion from stolen assets. Increased mixing activity was also noted, with 53 BTC entering CoinJoin transactions, indicating ongoing efforts to obscure the stolen funds' trail.
The Binance theft-linked wallets moving 44 million XRP provide context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, as of Nov 09, 2026 16:01 WIB, 6 out of 50 major cryptocurrencies rose while 43 fell. Notable movers include FIL at Rp13.522 with a 1-day change of -4.57%, LUNC at Rp0,696 down 4.40%, and THETA at Rp2.489 down 4.23%.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
